Marsault, Éric

Professeur, Faculté de médecine et des sciences de la santé
FMSS Département de pharmacologie-physiologie

Coordonnées

Courriel


819-821-8000, poste 72433


Site Web

Diplômes

(2002) Post-doctorate (NSERC Industrial Research Postdoctoral Fellowship). Néokimia.

(2000) Total synthesis of natural products. Post-doctorate (Postdoctoral Fellowship). Université de Sherbrooke.

(1996) Asymmetric synthesis of phosphorothioates. Doctorate (Ph.D.). McGill University.

(1993) Organic synthesis. Master's Equivalent (Diplôme de Chimiste ESCOM). Université de Paris VI (P & M Curie).

(1991) Bachelor's (Licence de Chimie). Université de Paris VI (P & M Curie).

Expérience académique

(2016) Full Professor, Medicinal Chemistry and Pharmacology. Université de Sherbrooke.

Présentation

Sujets de recherche

Chemical Synthesis and Catalysis, Organic Molecules and Biomolecules, Combinatorial Chemistry, Receptors and Carriers.

Disciplines de recherche

Chemistry, Pharmacology.

Mots-clés

combinatorial chemistry, drug design, drug discovery, enzyme inhibition, GPCRs, medicinal chemistry, molecular probe design, pharmacology, PK-ADME, SAR.

Intérêts de recherche

My research interests are in medicinal chemistry, and the creation of new molecules to better understand biological systems and provide drug candidates with improved side effect profiles. The following themes are underway: macrocycles for GPCRs and protein-protein interactions, covalent reversible inhibitors of serine proteases for influenza, new antibiotic agents and new cellular permeation agents.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français, Italien

Prix et distinctions

  • (2016) Kales Award for most impactful publication (Nature Commun. 2015). National Cancer Institute. (Prize / Award).
  • (2015) Prix de la Recherche et de la Création. Université de Sherbrooke. (Prize / Award).
  • Prix du doyen. Université de Sherbrooke. (Distinction).

Financement

Grant. (Awarded). Co-applicant. The small GTPase Rab4 as a target for breast cancer metastasis. Canadian Institutes of Health Research (CIHR). Project scheme. 1075000 $ (2019-2024).

Grant. (Awarded). Co-applicant. Role, function and regulation of the delta opioid receptor and its implications for the treatment of pain. Canadian Institutes of Health Research (CIHR). Project. 1265000 $ (2019-2024).

Grant. (Awarded). Principal Applicant. Exploiting ELABELA and Analogues to protect from septic shock. Canadian Institutes of Health Research (CIHR). Project. 707600 $ (2018-2023).

Grant. (Awarded). Co-applicant. Targeting endogenous repair: a novel mutation-independent pharmacological approach for the treatment of muscular dystrophy. Canada Stem Cell Network. Disruptive research program. 330000 $ (2020-2022).

Grant. (Awarded). Principal Applicant. Targeting the apelin receptor for the management of heart failure. Canadian Institutes of Health Research (CIHR). Project Scheme. 665000 $ (2017-2022).

Grant. (Awarded). Principal Applicant. Structural determinants of membrane permeability and cellular penetration. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery. 300000 $ (2017-2022).

Grant. (Awarded). Principal Applicant. Structure-function and dynamics of the apelin receptor, a promising target in the treatment of cardiovascular diseases. Fonds de recherche du Québec - Santé (FRQS). FRQS-China program on Cardiovascular Diseases. 600000 $ (2019-2022).

Grant. (Awarded). Principal Applicant. Bacterial ATP synthase inhibitors - A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacteria. Québec Consortium for Drug Discovery (CQDM). SynergiQc. 1459041 $ (2020-2021).

Grant. (Awarded). Co-applicant. New antibiotic combination for MRSA and P. aeruginosa in cystic fibrosis. Cystic Fibrosis Canada. Strategic Projects. 300000 $ (2018-2021).

Grant. (Awarded). Co-applicant. Maturation d'inhibiteurs de l'ATP synthétase bactérienne pour les infections à SARM difficiles à traiter et les infections à Gram positif et Gram négatif mixtes. AMORCHEM THERAPEUTICS. Strategic Partnerships. 895429 $ (2018-2020).

Grant. (Awarded). Principal Applicant. Peptide diversity generation apparatus to elucidate cell-molecules interactions. Natural Sciences and Engineering Research Council of Canada (NSERC). Research tools and Instruments. 149900 $ (2019-2020).

Grant. (Awarded). Principal Applicant. Dissiper la fumée - Potentiel thérapeutique et effets indésirables du cannabis. Canadian Institutes of Health Research (CIHR). Dissemination and planning grant. 15000 $ (2019-2020).

Grant. (Awarded). Co-applicant. The great escape: Improving the activity of chemotherapeutics delivered by antibody-drug conjugates with integrated endosome escape and nuclear-directional trafficking control capabilies. Canadian Institutes of Health Research (CIHR). Project Scheme. 738000 $ (2017-2020).

Grant. (Awarded). Co-applicant. Maturation d'inhibiteurs de l'ATP synthétase bactérienne pour les infections SARM difficiles à traiter et les infections à Gram négatif et Gram positif mixtes. Ministère de l'économie et de l'innovation du Québec. PSVT2b. 511101 $ (2019-2020).

Grant. (Awarded). Principal Applicant. Modulation de la signalisation du récepteur Neurotensine 1 à l'aide des pepducines. Fonds de recherche du Québec - Nature et technologies (FRQNT). Programme de recherche en équipes. 165000 $ (2017-2020).

Grant. (Awarded). Co-applicant. The small GTPase Rab4 as a target for breast cancer metastasis. Canadian Institutes of Health Research (CIHR). Operating Grants. 100000 $ (2019-2020).

Grant. (Awarded). Co-applicant. 20th Joint meeting of the Great Lakes GPCR Retreat and the Club des récepteurs à sept domaines transmembranaires du Québec. Canadian Institutes of Health Research (CIHR). Dissemination Grant. 20000 $ (2019).

Grant. (Awarded). Co-investigator. Bacterial ATP synthase inhibitors for difficult-to-treat MRSA infections and mixed Gram-negative and Gram-positive infections. Aligo Innovation. Strategic grants. 426000 $ (2018-2019).

Grant. (Awarded). Co-applicant. Apelinergic compounds for the treatment of muscular dystrophy. Canadian Stem Cell Network. Impact Research Agreement Program. 93400 $ (2018-2019).

Grant. (Awarded). Principal Applicant. Harnessing the apelin receptor and ELABELA to treat septic shock. Canadian Institutes of Health Research (CIHR). Operating grants. 100000 $ (2018-2019).

Contract. (Awarded). Principal Applicant. Library of macrocycles. Bayer. Contract research. 575000 $ (2017-2018).

Contract. (Completed). Principal Investigator. Generation of spatial epitopes for membrane targets (with Immune Biosolutions). Immune Biosolutions. Service contract. 72000 $ (2018).

Grant. (Completed). Principal Applicant. Improvement of the permeability of hydrophobic compounds with fatty acid derivatives (with neptune Bioresources). Natural Sciences and Engineering Research Council of Canada (NSERC). Engage. 25000 $ (2017-2018).

Grant. (Completed). Principal Applicant. Développement de tests pour la perméabilité hématoencéphalique. Centre des Neurosciences de Sherbrooke. Strategic projects. 10000 $ (2017).

Grant. (Completed). Principal Applicant. High throughput evaporator for medicinal chemistry. Natural Sciences and Engineering Research Council of Canada (NSERC). Research Tools and Instruments. 149600 $ (2016-2017).

Grant. (Awarded). Principal Investigator. Création d'une chimiothèque québécoise. Réseau Québécois de Recherche sur le Médicament. Projets stratégiques. 50000 $ (2015-2017).

Grant. (Completed). Principal Applicant. Extension of Réseau Québécois de Recherche sur le Médicament. Fonds de recherche du Québec - Santé (FRQS). Réseaux de recherche. 1215000 $ (2014-2017).

Grant. (Completed). Co-applicant. Upgrade of the Université de Sherbrooke 600 MHz solution state NMR platform for structural biology and pharmacology. Canada Foundation for Innovation (CFI). Leader's Opportunity. 800000 $ (2016-2017).

Grant. (Completed). Principal Applicant. Comprendre la signalisation du récepteur NTS1 avec de nouveaux modulateurs allostériques lipopeptidiques. Centre des neurosciences - Université de SHerbrooke. Projets Pilotes. 7500 $ (2016).

Publications

Articles de revue

  • C Binda, S Génier, S Picard, J Degrandmaison, L Fréchette, S Jean, E Marsault, JL Parent. (2019). L-type prostaglandin D synthase regulates the trafficking of the PGD2 DP1 receptor through an interaction with Rab4. J Biol Chem, tbd, tbd. (Accepted).
  • JR Simmons; A Murza; MD Lumsden; C Kenward; E Marsault; JK Rainey. (2019). Simultaneous ligand and receptor tracking through NMR spectroscopy enabled by distinct 19F labels. Int J Mol Sci, tbd, tbd. (Accepted).
  • Le Roux, A; Blaise, E; Boudreault, PL; Comeau, C; Doucet, A; Giarrusso, M; Collin, MP; Neubauer, T; Koelling, F; Goeller, A; Seep, A; Tshitenge, D; Wittwer, M; Kullmann, M; Hillisch, A; Mittendorf, J; Marsault, E. (2019). Structure-Permeability Relationship of Semi-Peptidic Macrocycles – Understanding and Optimizing Passive Permeability and Efflux Ratio. J Med Chem, (Submitted).
  • Béliveau F; Tarkar A; Ghinet MG; Dion SP; Boudreault PL; Désilets A; StGeorges C; Marsault E; Paone D; Collins J; Macphee CH; Campobasso N; Groy A; Cottom J; Ouellette M; Pope AJ; Leduc R. (2019). TMPRSS6 inhibitors increase hepcidin levels in hepatocytes. Cell Chem Biol, tbd(tbd), tbd. (Accepted).
  • Marsault, Eric; Llorens-Cortes, Catherine; Iturrioz, Xavier; Chung, Yun; Lesur, Oliviery Oudit, Gavin; Auger-Messier, Mannix. (2019). The apelinergic system: Perspective on challenges and opportunities in cardiovascular and metabolic disorders. Annals of the New York Academy of Sciences, tbd, tbd. (Accepted).
  • A Murza*, K Trân*, L Bruneau-Cossette*, O Lesur, M Auger-Messier, P Lavigne, P Sarret, E Marsault. (2018). Apelins, ELABELA and their derivatives : peptidic regulators of the cardiovascular system and beyond. Peptide Science (special issue dedicated to Peptide Science in Canada), tbd, tbd. (Accepted).
  • Kien Trân*, Alexandre Murza*, Xavier Sainsily, David Coquerel, Jérôme Côté, Karine Belleville, Jean-Michel Longpré, Robert Dumaine Dany Salvail, Olivier Lesur, Mannix Auger-Messier, Philippe Sarret, and Éric Marsault. (2018). A systematic exploration of macrocyclization in apelin-13 – impact on binding,signaling, stability and physiological effects. J Med Chem, 61, 2266-2277. (Published).
  • M Sousbie*, E Besserer-Offroy, RL Brouillette, JM Longpré, R Leduc, P Sarret, E Marsault. (2018). In search of the optimal macrocyclization site for neurotensin. ACS Med Chem Lett, 9, 227-232. (Published).
  • Klarskov K; Gagnon H; Boudreault PL; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S. (2018). Peak AAA fatty acid contaminants present in the dietary supplementL-Tryptophan associated with the onset of Eosinophilia-Myalgia syndrome. Toxicol Lett, 294, 193-204. (Published).
  • LH Yan*, A Le Roux*, K Boyapelly*, AM Lamontagne, MA Archambault, F Picard-Jean, D Lalonde-Séguin, E Saint-Pierre, R Najmanovich, LC Fortier, D Lafontaine, E Marsault. (2018). Purine analogs targeting the guanine riboswitch as potential antibiotics against Clostridium difficile. Eur J Med Chem, 143, 555-768. (Published).
  • M Lamontagne Boulet M; C Isabelle; I Guay ; E Brouillette ; JP Langlois ; PE Jacques ; S Rodrigue ; R Brzezinski ; K Bouarab ; E Marsault ; F Malouin . (2018). Staphylococcus aureus ATP synthase subunit C is the molecular target of tomatidine. Antimicrob. Agents Chemother., 62, e2197-2217. (Published).
  • M Sousbie*; M Vivancos; E Besserer-Offroy; R Brouillette; JM Longpré; R Leduc; P Sarret; E Marsault. (2018). Structural optimization and characterization of macrocyclic analogues of neurotensin 8-13. J Med Chem, 61, 227-232. (Published).
  • K Klarskov, H Gagnon, PL Boudreault*, C Normandin*, B Plancq*, E Marsault, GJ Gleich, S Naylor. (2018). Structure determination of disease-associatedpeak AAA from L-tryptophan implicated inthe eosinophilia-myalgia syndrome. Tox Lett, 282, 71. (Published).
  • D Coquerel, X Sainsily, P Sarret, E Marsaut, M Auger-Messier, O Lesur . (2018). The apelinergic system as an alternative to catecholamines in low-output septic shock. Crit Care, 22, 10. (Published).
  • E Besserer-Offroy, P Bérubé, J Côté, A Murza*, JM Longpré, R Dumaine, O Lesur, M Auger-Messier, R Leduc, E Marsault, P Sarret . (2018). The hypotensive effect of activated apelin receptor is correlated with beta-arrestin recruitment. Pharmacol Res, 131, 7-16. (Published).
  • Marsault E. (2018). Une nouvelle classe de macromolécules polycationiques à l’assaut des pathogènes multirésistants. Médecine Sciences, tbd(tbd), tbd. (In Press).
  • F Chagnon, D Coquerel, D Salvail, E Marsault, R Dumaine, M Auger-Messier, P Sarret, O Lesur. (2017). Apelin over dobutamine exerts cardioprotection and extends survival in a rat model of endotoxin-induced myocardial dysfunction. Crit Care Med, 45, 391-398. (Published).
  • D Coquerel, F Chagnon, X Sainsily, L Dumont, A Murza*, J Côté, R Dumaine, P Sarret, E Marsault, D Salvail, M Auger-Messier, O Lesur . (2017). Elabela improves cardio-renal syndrome and outcome in fatal experimental septicshock. Crit Care Med, tbd, tbd. (Accepted).
  • E Marouseau*, A Neckebroeck*, H Larkin, A Le Roux*, L Volkov, C Lavoie, E Marsault. (2017). Modular sub-monomeric cell-penetrating peptoids – Synthesis, assembly and biological evaluation. RSC Advances, 7, 6059-6063. (Published).
  • E Besserer-Offroy, R Brouillette, S Lavenus, A Brumwell, A Murza*, JM Longpré, E Marsault, M Grandbois, P Sarret, R Leduc. (2017). Signaling signature of neurotensin receptor type 1 agonists. Eur J Pharmacol, NA(805), 1-13. (Published).
  • A Murza*, X Sainsily, J Côté, L Bruneau-Cossette*, E Besserer-Offroy, JM Longpré, R Leduc, R Dumaine, O Lesur, M Auger-Messier, P Sarret, E Marsault. (2017). Structure-activity relationship of novel macrocyclic biased apelin receptor agonists. Org Biomol Chem, 15, 449-458. (Published).
  • C St-Georges*, A Désilets, F Béliveau, M Ghinet, SP Dion, É Colombo*, PL Boudreault*, RJ Najmanovich, R Leduc, E Marsault. (2017). Synthesis and Characterization of Potent and Selective Matriptase-2 Inhibitors. Eur J Med Chem, 129, 110-123. (Published).
  • K Boyapelly*; MA Bonin;* H Traboulsi*; A Cloutier; A Cantin; M Richter; E Marsault. (2017). Synthesis and characterization of a phosphate prodrug of isoliquiritigenin. J Nat Prod, 80, 879-886. (Published).
  • M Paquette, L Guillermo Vilera-Perez, S Beaudoin, N Ekindi-Ndongo, PL Boudreault*, MA Bonin*, MC Battista, M Bentourkia, AF Lopez, R Lecomte, E Marsault, B Guérin, R Sabbagh, JV Leyton. (2017). Targeting IL5Ra with antibody-conjugates revealsa strategy for imaging and therapy forinvasive bladder cancer. Oncoimmunology, 19, e1331195. (In Press).
  • I Guay, S Boulanger, E Brouillette, F Chagnon*, K Bouarab, E Marsault, F Malouin. (2017). Tomatidine and analog FC04-100 possess bactericidal activities against the small colony variants of some Firmicutes including those of Liseria monocytogenes and are bactericidal in combinationwith aminoglycosides against their normal phenotype. BMC Pharmac Toxicol, tbd, tbd. (Submitted).
  • LJ Deny*, H Traboulsi, A Cantin, E Marsault, MV Richter, G Bélanger. (2016). Bis-Michael acceptors as novel probes to study the Keap1/Nrf2/ARE pathway. J Med Chem, 59, 9431-9442. (Published).
  • C Mona*, E Besserer-Offroy, J Cabana, R Leduc, P Lavigne, N Heveker, E Marsault, E Escher. (2016). Design, synthesis and biological evaluation of CXCR4 ligands. Org Biomol Chem, 14, 10298-10311. (Published).
  • A Murza*, X Sainsily, D Coquerel, J Côté, P Marx*, E Besserer-Offroy, JM Longpré, J Lainé, B Reversade, D Salvail, R Dumaine, R Leduc, M Auger-Messier, O Lesur, E Marsault. (2016). Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J Med Chem, 25, 2962-2972. (Published).
  • H Souissi, Y Fréchette, A Murza*, MH Masse, E Marsault, P Sarret, F d’Aragon, AJ Parent, Y Sansoucy. (2016). Intracuff 60 mg alkalinized lidocaine reduces cough upon emergence from general anesthesia without N2O: a randomized controlled trial. Canadian Journal of Anesthesia & Analgesia, 862-870. (Published).
  • GL Zoratti, LM Tanabe, MJ Duhaime, E Colombo*, R Leduc, E Marsault, MD Johnson, CY Lin, J Boerner, JE Lang, K List. (2016). Matriptase promotes c-Met mediated proliferation and invasion in inflammatory breast cancer. Oncotarget, 7, 58162-73. (Published).
  • C Mona*, E Besserer-Offroy, J Cabana, M Lefrançois, P Boulais, MR Lefebvre, R Leduc, P Lavigne, N Heveker, E Marsault, E Escher. (2016). Structure-activity relationship of CXCR4 agonists:pharmacophore discovery and associated signaling pathways. J Med Chem, 25, 7512-24. (Published).
  • A Murza*, E Besserer-Offroy, J Côté, P Bérubé, JM Longpré, R Dumaine, O Lesur, M Auger-Messier, R Leduc, P Sarret, E Marsault. (2015). C-terminal modifications of apelin-13 change ligand binding, receptor signaling and hypotensive action. J Med Chem, 58, 2431-2440. (Published).
  • H Traboulsi*, H Larkin, MA Bonin*, CL Lavoie, E Marsault*. (2015). Macrocyclic cell penetrating peptides: a study of structure-activity relationship. Bioconj Chem, 26, 405-11. (Published).
  • GL Zoratti; LM Tanabe; C Bergum; E Colombo*; C Kuperwasser; JE Lang; AA Molinolo; R Leduc; E Marsault; J Boerner; K List*. (2015). Protease-mediated signaling in breast cancer: matriptase is required for activation of HGF/c-Met driven proliferation and invasion. Nat Commun, 15, 6776-6789. (Published).
  • F Chagnon, A Bourgouin, R Lebel, MA Bonin*, E Marsault, M Lepage, O Lesur. (2015). Smart imaging of acute lung injury: validation of myeloperoxidase (MPO) activity using in vivo endoscopic confocal fluorescence microscopy (ECFM). Am J Physiol, 309, 543-551. (Published).
  • AP Treder*, MC Tremblay*, J Hickey, S Zaretsky, C Scully, J Mancuso*, A Doucet*, A Yudin, E Marsault. (2015). Solid phase synthesis of macrocyclic peptides via 3-component coupling with aziridine aldehyde dimers. Chem: A Eur J, 21, 9249-9255. (Published).
  • A Bourgouin*, R Lebel, MA Bonin*, O Lesur, E Marsault, M Lepage. (2015). Synthesis and in vitro characterization of a fluorescent probe for myeloperoxidase activity detection. Contrast Media Mol Imag, tbd, tbd. (Submitted).
  • S Boulanger, G Mitchell, K Bouarab, E Marsault, A Cantin, E Frost, E Déziel, F Malouin. (2015). The bactericidal effect of the tomatidine and tobramycin combination against MRSA and P aeruginosa is enhanced by interspecific small molecule interactions. J Antimicrob Chem, 7458-7464. (Published).
  • H Traboulsi, A Cloutier, K Boyapelly, MA Bonin*, E Marsault, AM Cantin, MV Richter. (2015). The natural flavonoid isoliquiritigenin reduces lung inflammation and protects mice against influenza infection. Antimicrob. Ag. Chemother., 59, 6317-6327. (Published).
  • D Duchêne*, E Colombo*, A Désilets, R Leduc, E Marsault, R Najmanovich. (2014). Analysis of sub-pocket druggability and detection of potent selective inhibitors of the matriptase-2 human protease. J Med Chem, 57, 10198-204. (Published).
  • M Demeule, N Beaudet, A Regina, E Besserer, A Murza*, P Tétreault, K Belleville, C Ché, A Larocque, C Thiot, R Béliveau, JM Longpré, E Marsault, R Leduc, J Lachowicz, SL Gonias, JP Castaigne, P Sarret. (2014). Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J Clin Invest, 124, 1199-1213. (Published).
  • H Tremblay*, C St-Georges*, MA Legault*, C Morin, S Fortin, E Marsault. (2014). One-pot synthesis of polyunsaturated fatty acid amides with anti-proliferative properties. Bioorg Med Chem Lett, 24, 5635-5638. (Published).
  • AP Treder*, MC Tremblay*, AK Yudin, E Marsault. (2014). Solid-phase synthesis of piperazinones via disrupted Ugi condensation. Org Lett, 16, 4674-7. (Published).
  • A Murza*; K Belleville; JM Longpré; P Sarret; E Marsault. (2014). Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid. Biopolymers, 101, 297-303. (Published).
  • F Chagnon*, I Guay, MA Bonin*, M Lafrance, G Mitchell, F Malouin, K Bouarab, E Marsault*,. (2014). Structure-Activity Relationships of new tomatidine analogs against small colony variants of Staphylococcus aureus. Eur J Med Chem, 80, 605-620. (Published).
  • A Murza, A Parent, H Tremblay, F Karadereye, E Besserer-Offroy, P Sarret, E Marsault*. (2014). Structure-activity relationships, signaling and plasma stability of apelin analogs incorporating unnatural amino acids. ChemMedChem, 7, 318-325. (Published).
  • Le Roux, Antoine*; Marsault, Eric. (2013). Efficient synthesis of 2-urea substituted guanines. Synthesis, 45, 1983-1990. (Published).
  • C Ster, M Allard, S Boulanger, M Lamontagne Boulet, J Mulhbacher, DA Lafontaine, E Marsault, P Lacasse, F Malouin*. (2013). Experimental treatment of Staphylococcus aureus bovine intramammary infection using PC1, a guanine riboswitch ligand analog. J Dairy Sci, 1000-1008. (Published).
  • Beaulieu, A.; Gravel, E; Cloutier, A; Colombo, E*; Désilets, A; Verreault, C; Leduc, R; Marsault, E; Richter, MV. (2013). Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium. J Virol, 87, 4237-4251. (Published).
  • E Colombo*, F Chagnon*, A Désilets, D Duchêne*, R Najmanovich, R Leduc, E Marsault*. (2012). Design and synthesis of new inhibitors of matriptase. ACS Med Chem Lett, 530-534. (Published).
  • Murza A*, Parent A , Besserer-Offroy E , Tremblay H*, Karadereye F*, Beaudet N , Leduc R , Sarret P , Marsault É. (2012). Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. ChemMedChem, 7, 318-325. (Published).
  • G Mitchell, M Lafrance, S Boulanger, D Lalonde Séguin, I Guay, M Gattuso, E Marsault, K Bouarab, F Malouin*. (2012). Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression. J Antimicrob Chemother, 67, 559-68. (Published).
  • E Marsault; ML Peterson. (2011). Macrocycles are greatcycles: applications, challenges and opportunities of synthetic macrocycles indrug discovery. J Med Chem, 54, 1961-2004. (Published).
  • HR Hoveyda; E Marsault, R Gagnon, AP Mathieu*, M Vézina*, A Landry*, Z Wang*, K Benakli*, S Beaubien*, C Saint-Louis*, M Brassard, JF Pinault, L Ouellet*, S Bhat, M Ramaseshan, X Peng, L Foucher, S Beauchemin*, P Bhérer, DF Veber, ML Peterson, GL Fraser. (2011). Optimization of aMacrocyclic Ghrelin Receptor Agonist: Development of Ulimorelin (TZP-101) fromHit to Clinic. J Med Chem, 54, 8305-8320. (Published).
  • G Mitchell, M Gattuso, G Grondin, E Marsault, K Bouarab, F Malouin. (2011). Tomatidine inhibitsthe replication of staphylococcus aureus Small-Colony Variant in cysticfibrosis airway epithelial cells. Antimicrob. Agents Chemother, 1937-1945. (Published).
  • Marsault E, Hoveyda HR, Gagnon R, Peterson ML, Vézina M*, Saint-Louis C*, Landry A*, Pinault JF, Ouellet L*, Beauchemin S*, Beaubien S*, Mathieu A, Benakli K*, Wang Z, Brassard M, Lonergan D, Bilodeau F, Ramaseshan M, Fortin N*, Lan R, Li S, Galaud F, Plourde V*, Champagne M, Doucet A, Bhérer P, Gauthier M, Olsen G, Villeneuve G, Bhat S*, Foucher L, Fortin D, Peng X*, Bernard S*, Drouin A*, Déziel R, Berthiaume G, Dory YL, Fraser GL, Deslongchamps P. (2008). Efficient ParallelSynthesis of Macrocyclic Peptidomimetics. Bioorg Med Chem Lett, 18, 4731-4735. (Published).
  • H Thomas, N Berthiaume, E Kneebone, L Clohs, E Fournier, ML Peterson, E Marsault, R Brandt. (2008). The ghrelin receptor agonist TZP-101 is a potent anti-tumor cachexiaagent in the human G361 melanoma mouse xenograft model. Eur J Can, 6, 107. (Published).
  • E Marsault, K Benakli*, C Saint-Louis*, S Beaubien*, R Déziel, GL Fraser. (2007). Potent, MacrocyclicMotilin Antagonists Incorporating New Unnatural Amino Acids. Bioorg Med Chem Lett, 2007, 4187-4191. (Published).

Livres

  • E Marsault, ML Peterson. (2017). Practical medicinal chemistry with macrocycles (Wiley). United States : Wiley. (Published).

Chapitres de livre

  • Marsault E; Peterson ML. (2017). Editor. Marsault E; Peterson ML Practical Medicinal Chemistry with Macrocycles (1-600). United States : Wiley (Hoboken). (Published).
  • Hoveyda, HR; Fraser, GL; Marsault, E; Gagnon, R; Peterson, ML. (2017). Optimization of a macrocyclic ghrelin receptor agonist (Part II): Development of TZP-102. Marsault E; Peterson ML Practical Medicinal Chemistry with Macrocycles (x-y). United States : Wiley (Hoboken). (Published).
  • Hoveyda, HR; Fraser, GL; Marsault, E; Gagnon, R; Peterson, ML. (2017). Optimization of a macrocyclic ghrelin receptor agonist (part II): Development of TZP-102. Marsault, E; Peterson, ML Practical medicinal chemistry with macrocycles (545-558). United States : Wiley. (Published).
  • Marsault, E. (2013). Macrocycles as templates for diversity-oriented synthesis. A. Trabocchi Diversity-oriented synthesis (230-262). United States : Wiley. (In Press).
  • Peterson, Mark; Hoveyda, Hamid; Fraser, Graeme; Marsault, Eric; Gagnon, René. (2013). Use of macrocycles in drug design exemplified with Ulimorelin, a ghrelin agonist for gastrointestinal motility disorders. Fischer, Ganellin, Rotella Analogue-based drug discovery III (IUPAC series); Janos Fischer; C. Robin Ganellin; David P. Rotella Eds (77-104). United States : Wiley. (Published).

Propriétés intellectuelles

Patents

  • Marsault E; Boudreault PL; Traboulsi H; Sarret P; Nepveu-Traversy ME; Gaudreau S; Leduc F; Larivée JF; Arcand M. Antibodies specific for NTS1R and uses thereof. 1. US62/725,451. United States. (Pending).
  • Guanine riboswitch binding compounds and their use as antibiotics. WO 2010/142027 A1. United States. (Granted/Issued).
  • Richter M; Colombo E; Leduc R; Marsault E. Inhibitors of matriptase for the treatment of influenza. NA. United States. (Pending).
  • Marsault E; Sousbie M; Leduc R; Sarret P; Longpré JM; Besserer-Offroy E; Brouillette R. Macrocyclic agonists of the neurotensin receptor. NA. United States. (Pending).
  • Marsault E; Sousbie M; Leduc R; Sarret P; Longpré JM; Besserer-Offroy E; Brouillette R. Macrocyclic compounds and methods of preventing or treating pain. USPTO 62520980. United States. (Pending).
  • Boudreault PL; Colombo E; Leduc R; Marsault E; Plancq B; Richter M. Matriptase inhibitors and uses thereof. NA. United States. (Pending).
  • Boudreault, PL; Colombo, E; Leduc, R; Marsault, E; Plancq, B; Richter, M. Matriptase inhibitors and uses thereof. NA. United States. (Pending).
  • Boudreault, PL; Colombo, E; Leduc, R; Marsault, E; Plancq, B; Richter, M. Matriptase inhibitors and uses thereof. NA. United States. (Pending).
  • Matriptase inhibitors and uses thereof against orthomyxoviridae infections. US61/492556. United States. (Pending).
  • Hickey J; Mancuso J; Marsault E; Roughton A; Treder AP; Tremblay MC; Yudin AK; Zaretsky S. Solid phase synthesis of cyclic amino acid molecules. PCT62,081,780. United States. (Pending).
  • Use of steroid alkaloids as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria and uses thereof. US 61/442,948. United States. (Pending).
  • Marsault E; Malouin F; Chagnon F; Guay I; Boulanger S. steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria. 1. PCT 61/919,896. United States. (Pending).

Licenses

  • Research agreement with licence: matriptase inhibitors for the treatment of influenza. A joint development project with neomed has been initiated, in which Neomed has an option to licence the technology. (Granted).

Autres contributions

Cours enseignés

  • Chimie médicinale. BCM504. Niveau : Undergraduate. (3CR).
  • Medicinal Chemistry (Advanced). PHR714. Niveau : Graduate. (2CR).
  • Molecular endocrinology. BCM606. Niveau : Undergraduate. (3CR).
  • Principles of Pharmacology. PHR701. Niveau : Graduate. (2CR).

Gestion d'évènements

  • Organizer. (2018). Drug design for the apelin receptor across diverse pathophysiological indications - RegPep 2018. (Conference).
  • Organizer. (2013-2018). COurse on Macrocycles Drug Discovery - CHI's Macrocycles and Constrained Peptides - San Diego (yearly event). (Course).
  • co-chair. (2013). CSC Biological & Medicinal Chemistry Session 2013. (Conference).
  • Organizer. (2013). CSC Meeting in Québec - Emerging models of academic drug discovery. (Conference).
  • co-organizer. (2011). Journée Phare 2011. (Conference).
  • Organizer. (2011). ACFAS Medicinal Chemistry session May 2011. (Conference).

Activités de collaboration internationale

  • Collaborator. (2014-2020). United States. Collaboration on elucidating the role of matriptase in inflammatory breast cancer Involves the teams of Karin List (U. Washington) Julie Lang (U. California).
  • Collaborator. (2015-2020). Australia. Collaboration with the Community - Antibiotic Drug Discovery (Wellcome Trust) on the discovery of novel antibiotics against ESKAPE pathogens. Involves the Quebec Library of compounds (FRQS- funded).
  • collaborator. (2017-2020). United Kingdom. Crystallization of the ATP synthase of S. aureus with small molecule inhibitors.
  • Collaborator. (2016-2020). Singapore. Decipher the physiological roles of ELABELA.
  • Collaborator. (2016-2018). United States. Collaboration on the crystallization of the apelin (APJ) receptor with the lab of Pr. Ray Stevens (U. South California - Los Angeles).
  • Collaborator. (2014-2017). Canada. Collaboration with Elanco Canada and Pr. François Malouin (U. Sherbrooke) on the optimization of novel riboswitch inhibitors for the treatment of bovine mastitis.
  • Principal investigator. (2013-2016). Germany. Collaboration with Bayer on the design and synthesis of new macrocycles.
  • Principal Investigator. (2011-2014). Japan. Collaboration on the discovery of mixed GPR40/GPR120 agonists with Pr. Gozoh Tsujimoto.

Présentations

  • (2017). Structure-permeability relationship of semi-peptidic macrocycles. Cambridge Healthtech Institute's Macrocycles & Constrained Peptides. San Diego, United States.
  • (2017). TTSPs: emerging targets to fight influenza. Selectbio's Academic Drug Discovery. Cambridge, United Kingdom.
  • (2017). The Apelin receptor. INRS - Institut Armand Frappier Annual Symposium. Orford, Canada.
  • C Isabelle, M Lamontagne-Boulet, F Chagnon, K Bouarab, E Marsault, F Malouin. (2017). The cellular target of tomatidine and analogs against Staphylococcus aureus is the bacterial ATP synthase. European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria.
  • A Murza, X Sainsily, D Coquerel, J Côté, P Marx, E Besserer-Offroy, JM Longpré, O Lesur, M Auger-Messier, P Sarret, E Marsault. (2016). Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. GPCR Retreat. CHicago, United States.
  • L Dumont, D Coquerel, X Sainsily, A Murza, R Dumaine, E Marsault, P Sarret, M Auger-Messier, O Lesur. (2016). Elabela exerce une protection cardiovasculaire supérieure à l’apéline dans le choc septique. 58e réunion annuelle du Club de Recherche Clinique du Québec. Québec, Canada.
  • E Marsault, PL Boudreault, A Griffin, B Brown, R Leduc, M Richter. (2016). Host-based inhibitors of type 2 transmembrane serine proteases as a promising approach for the treatment of influenza. Tetrahedron Symposium. Barcelona, Spain.
  • C Comeau, G Leclair, E Marsault. (2016). Investigating the Permeability of Semi-peptidic Macrocycles. Canadian Society for Chemistry National Meeting. Halifax, Canada.
  • (2016). Les peptides comme outils pour comprendre la biologie. Université Laval. Quebec, Canada.
  • K Tran, A Murza, X Sainsily, J Côté, D Coquerel, JM Longpré, O Lesur, M Auger-Messier, P Sarret, E Marsault. (2016). Macrocycle mimics active conformation of apelin-13. Regulatory Peptides 2016. Rouen, France.
  • (2016). Macrocyclic semipeptides: from GPCR drug discovery to structure-permeability relationship. RSC's Medicinal Chemistry and beyond the Rule of Five. Zagreb, Croatia.
  • E Marsault. (2016). Matriptase as an emerging target for the treatment of influenza. Cambridge Healthtech Institute's Antivirals. San Diego, United States.
  • E Marsault, A Murza, K Trân, X Sainsily, D Coquerel, J Côté, E Besserer-Offroy, JM Longpré, R Dumaine, O Lesur, P Sarret. (2016). Modulating the structure of Apelin to bias signalling of the APJ receptor : impact and potential in cardiovascular diseases. Canadian Society for Chemistry National Meeting. Halifax, Canada.
  • E Marsault. (2016). Molecular Engineering of Apelin and implications for cardiac and vascular functions. Regulatory Peptides 2016. Rouen, France.
  • Élie Besserer-Offroy, Christine Mona, Pierre-Luc Boudreault, Jean-Michel Longpré, Richard Leduc, Éric Marsault, and Philippe Sarret. (2016). Phosphomimetic lipopeptides as new tools to investigate ?-arrestin-mediated functions. National Society for Neurosciences. San Diego, United States.
  • C St-Georges, A Désilets, SP Dion, PL Boudreault, R Najmanovich, R Leduc, E Marsault. (2016). Synthesis and Characterization of Potent and Selective Inhibitors for Matriptase-2. Canadian Society for Chemistry National Meeting. Halifax, Canada.
  • E Marsault. (2016). Type 2 serine protease inhibitors as an emerging host-based treatment for influenza. University of Bonn Seminar series. Bonn, Germany.
  • E Marsault. (2016). Type 2 serine proteases as a potential host-based treatment aganst influenza. 17th Annual Drug Discovery Leaders summit. Berlin, Germany.
  • A Le Roux, E Blaise, A Doucet, M Giarrusso, MP Collin, T Neubauer, F Koelling, M Wittwer, A Hillish, J Mittendorf, E Marsault. (2016). Understanding the structure-permeability relationship of semi-peptidic macrocycles. Cambridge Healthtech Institue’s Macrocycles & Constrained Peptides. San Diego, United States.
  • E Marsault. (2016). Validating matriptase for the treatment of influenza. German Chemical Society. Bonn, Germany.
  • A Tiffinger, EA Ouellet, D Coquerel, F Chagnon, E Marsault, M Auger-Messier, P Sarret, O Lesur, R Dumaine. (2016). Étude des effets inotropes positifs de l’apéline sur des cardiomyocytes de rat adulte. 58e réunion annuelle du Club de Recherche Clinique du Québec. Québec, Canada.
  • (2015). Advances in the optimization of a new approach for the synthesis of macrocycle libraries. Bayer Healthcare Research Institute. Wuppertal, Germany.
  • PL Boudreault, M Azzi, A Griffin, B Brown, R Leduc, M Richter and E Marsault. (2015). A successful industry-academia collaboration toward the development of new host-based antivirals against influenza. Pacifichem. Honolulu, United States.
  • E Marsault, F Chagnon, I Guay, M Lamontagne Boulet; F Malouin. (2015). Deciphering the structure-activity relationships of tomatidine, a steroid alkaloid with antibiotic properties against small colony variants of Staphylococcus aureus. Pacifichem. Honolulu, United States.
  • V Belley, C Ster, E Brouillette, AM Lamontagne, D Lafontaine, A Leroux, K Boyapelly, E Marsault, P Lacasse, F Malouin. (2015). Development of guanine riboswitch ligands with antibacterial activity against Staphylococcus aureus. European Society of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark.
  • PL Boudreault, E Colombo, P Thakur, E Gravel, A Désilets, I Marois, D Cliche, A Cloutier, A Griffin, B Brown, R Leduc, M Richter and E Marsault. (2015). Host-based serine protease inhibitors as an emerging treatment against influenza. Pacifichem. Honolulu, United States.
  • M Lamontagne-Boulet, I Guay, S Rodrigue, PE Jacques, RBrzezinski, K Bouarab, E Marsault, F Malouin. (2015). Identification of mutations associated with a reduced susceptibility of Staphylococcus aureus Small Colony Variants to tomatidine. European Society of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark.
  • ML Peterson. (2015). Macrocycles in Drug DIscovery - a Short Course. Cambridge Healthtech Institute's Macrocycles and Constrained Peptides. San Diego, United States.
  • M Sousbie, E Besserer-Offroy, JM Longpré, P Sarret, E Marsault. (2015). Macrocyclic analogues of Neurotensin 8-13: effect of conformational restriction in ligand binding and signalling. American Peptide Symposium. Orlando, United States.
  • M Sousbie, É Besserer-Offroy, JM Longpré, P Sarret, R Leduc, E Marsault. (2015). Macrocyclic analogues of neurotensin 8-13 : effect of conformational restriction on ligand binding and signalling. Great Lakes GPCR Retreat. Toronto, Canada.
  • M Sousbie, E Besserer-Offroy, JM Longpré, P Sarret, R Leduc, E Marsault. (2015). Macrocyclic analogues of neurotensin 8-13: effect of conformational restrictions on ligand binding and signalling. Canadian Society for Chemistry Meeting. Ottawa, Canada.
  • E Marsault, A Murza, É Besserer-Offroy, J Côté, JM Longpré, P Sarret. (2015). Modulating the apelin (APJ) receptor signaling with macrocycles. Pacifichem. Honolulu, United States.
  • C Comeau, P Hogan, M-C J. Tremblay, M-A Bonin, J-L Parent, A de Brum-Fernandes and E Marsault. (2015). New analogs of PGD2 for the treatment of bone diseases. Canadian Society for Chemistry Meeting. Ottawa, Canada.
  • PL Boudreault, E Colombo, P Thakur, E Gravel, A Désilets, I Marois, D Cliche, A Cloutier, R Leduc, M Richter, E Marsault. (2015). Peptidomimetic inhibition of host-targeted serine proteases as a treatment against influenza. Canadian Society for Chemistry Meeting. Ottawa, Canada.
  • H Traboulsi, H Larkin, MA Bonin, L Volkov, CL Lavoie, E Marsault. (2015). Polyarginine macrocyclic peptides for cell penetration: a study of structure-uptake relationship. Canadian Society for Chemistry Meeting. Ottawa, Canada.
  • J Hickey, SK Chakka, MA StDenis, M Morshed, AP Treder, MCJ Tremblay, CCG Scully, S Zaretsky, J Mancuso, A Doucet, E Marsault, AK Yudin, AL Roughton. (2015). Synthesis and characterization of nacellins, a novel class of macrocyclic peptidomimetics. American Peptide Symposium. Orlando, United States.
  • (2015). Type 2 serine proteases as emerging targets for the treatment of influenza. ASBMB's special symposium on membrane-anchored serine proteases. Potomac, United States.
  • A. Parent, P. Tétreault, É Besserer-Offroy, A. Murza, P. Bérubé, A. René, I. Dubuc, J.M. Longpré, N. Beaudet, R. Leduc, E. Marsault, J. Martinez, F. Cavelier, P. Sarret. (2014). Analgesic potency of a new neurotensin analog in different experimental models. 5th GPCR Retreat. Bromont, Canada.
  • O Lesur, F Chagnon, D Salvail, A Murza, E Marsault. (2014). Apelin is cardioprotective and life-saving over dobutamine in a murine model of endotoxin-induced myocardial dysfunction. Annual Congress of the European Society of Intensive Care Medicine. Barcelona, Spain.
  • E. Besserer-Offroy, A. Murza, P. Bérubé, T. Dinh, J.M. Longpré, R. Leduc, E. Marsault, P. Sarret. (2014). C-terminal modifications of apelin-13: generation of new biased analogs and impact on hypotensive effect. 15th GPCR Retreat. Bromont, Canada.
  • E Marsault; A Murza; E Besserer-Offroy; P Bérubé; JM Longpré; P Sarret. (2014). Deciphering the structure-activity relationship of apelin with unnatural amino acids and macrocycles. European Peptide Symposium. Sofia, Bulgaria.
  • A Murza, E Besserer-Offroy, P Bérubé, JM Longpré, P Sarret, E Marsault. (2014). Design, synthesis and SAR of new macrocyclic analogs of apelin-13. Canadian Society for Chemistry National Meeting. Vancouver, Canada.
  • A. Murza, E. Besserer-Offroy, P. Bérubé, J.M. Longpré, P. Sarret, E. Marsault. (2014). Design, synthesis and structure-activity relationship studies of new macrocyclic derivatives of apelin-13. 15th GPCR Retreat. Bromont, Canada.
  • S. Dion; A. Désilets; E. Colombo; E. Marsault; R. Leduc. (2014). Développement d’inhibiteurs de TMPRSS6, une cible dans les maladies associées au métabolisme du fer. Club des Recherches Cliniques du Québec. Québec, Canada.
  • E Marsault. (2014). Modulating the apelin signaling with unnatural amino acids and macrocycles. CHI's Macrocycles and constrained peptides. San Diego, United States.
  • E Marsault. (2014). Modulating the signaling of the APJ receptor with macrocycles. GTC's Drug Design & Medicinal Chemistry Conference. Berlin, Germany.
  • Frederic Chagnon, Alexandra Bourgouin, Marc-André Bonin, Réjean Lebel, Eric Marsault, Olivier Lesur, Martin Lepage. (2014). Molecular Imaging of Acute Lung Injury: Detection of Myeloperoxidase (MPO) Activity Using in vivo Confocal Fluorescence Endomicroscopy. World Molecular Imaging Congress. Seoul, Korea, Republic of.
  • E Marsault, E Colombo, P Thakur, PL Boudreault, I Marois, A Désilets, R Leduc, M Richter. (2014). New peptidomimetic inhibitors of matriptase against influenza. European Peptide Symposium. Sofia, Bulgaria.
  • A Bourgouin, F Chagnon, MA Bonin, R Lebel, E Marsault, M Lepage, R Bartha, O Lesur. (2014). Synthèse et validation in vitro/in vivo/ex vivo de sondes intelligentes activables (smart probes) dans le système respiratoire:. Journée scientifique du réseau de Bio-Imagerie du Québec. Montreal, Canada.
  • E Marsault. (2014). Toward new blockers of influenza replication. Canadian Society for Chemistry National Meeting. Vancouver, Canada.
  • E Marsault. (2014). Validating matriptase as anovel approach against influenza. Center for Drug Research and Development. Vancouver, Canada.
  • Marsault, E. (2013). Academic drug discovery. first RQRM-Neomed Scientific day. Montreal, Canada.
  • Desroches A; Boucher D; Blais V; Marsault E; Denault JB. (2013). Caractérisation de l’interaction caspase-7/PARP-1. 2e journée scientifique du RQRM. Montreal, Canada.
  • Besserer-Offroy E; Tétreault P; Lafrance M; Murza A; René A; Longpré JM; Cavelier F; Martinez J; Marsault E; Leduc R; Sarret P. (2013). Deciphering the NTS1 receptor signalling pathways leading to analgesia and hypothermia. Annual meeting - Society for Neurosciences. San Diego, United States.
  • Marsault, E. (2013). Design et optimisation de nouveaux inhibiteurs de la matriptase pour le traitement de l’influenza. ACFAS symposium, Nouveaux développements dans la chimie peptidique. Québec, Canada.
  • Marsault, E. (2013). Exploiting privileged structures to identify new GPCR ligands. Journée scientifique du RQRM. Montreal, Canada.
  • Tremblay H; Hirasawa A; Tsujimoto G; Marsault E. (2013). Exploring the chemical space of GPR40 and GPR120 with small molecules. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Tremblay H; Hirasawa A; Tsujimoto G; Marsault E. (2013). Exploring the chemical space of GPR40 and GPR120 with small molecules. ACS National Meeting. New Orleans, United States.
  • Marois I; Morisseau O; Gravel E; Colombo E; Leduc R; Marsault E; Richter M. (2013). Identification de nouveaux composes ciblant les proteases impliquées dans la replication du virus de l’influenza. 55e reunion annuelle du Club des Recherche Cliniques du Québec. Québec, Canada.
  • Lafrance M; Murza A; Besserer-Offroy E; Longpré JM; Leduc R; Stroh T; Marsault E; Sarret P. (2013). Impact of the incorporation of unnatural amino acids at the C-terminal end of the apelin peptide on pain inhibition. 8th EFIC – Pain in Europe Meeting Oct 2013. Florence, Italy.
  • Murza A; Besserer-Offroy E; Lafrance M; Parent A; Beaudet N; Leduc R; Sarret R; Marsault E. (2013). Incorporation of unnatural amino acids in apelin: influence on biased signalling and activity in animal models of pain. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • 5. Murza A; Besserer-Offroy E; Lafrance M; Parent A; Beaudet N; Leduc R; Sarret R; Marsault E. (2013). Incorporation of unnatural amino acids in apelin: influence on biased signalling and activity in animal models of pain. 2e journée scientifique du RQRM. Montreal, Canada.
  • Marsault, E. (2013). Les inhibiteurs de serine proteases de type 2 comme cibles émergentes pour combattre l’influenza. Proteo retreat. Laval, Canada.
  • Marsault, E. (2013). Lessons learned from a collaborative, CQDM-sponsored project. OCE-CQDM Life Sciences R&D Challenge Forum. Toronto, Canada.
  • Marsault, E. (2013). Macrocycle drug discovery. Bayer. Wuppertal, Germany.
  • Yan LH; Le-Roux A; Boyapelly K; Lamontagne AM; Lalonde-Séguin D; Fortier LC; Lafontaine D; Marsault E. (2013). New guanine riboswitch inhibitors as potential antibiotics targeting Clostridium difficile. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Colombo E; Désilets A; Beaulieu A; Marois I; Duchêne D; Najmanovich R; Leduc R; Richter M; Marsault E. (2013). New matriptase inhibitors as anti-influenza agents. ACS National Meeting. New Orleans, United States.
  • Marsault E; Colombo E; Duchêne D; Désilets A; Najmanovich R; Beaulieu A; Gravel E; Cloutier A; Marois I; Leduc R; Richter N. (2013). New matriptase inhibitors as potent anti-influenza agents. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • 7. Colombo E; Duchêne D; Désilets A; Marois I; Morisseau O; Beaulieu A; Gravel E; Najmanovich R; Richter M; Leduc R; Marsault E. (2013). New matriptase inhibitors as potential treatment against influenza. 2e journée scientifique du RQRM. Montreal, Canada.
  • Colombo E; Désilets A; Marois I; Morisseau O; Gravel E; Beaulieu A; Duchêne D; Najmanovich R; Richter M; Leduc R; Marsault E. (2013). New potent peptidomimetic inhibitors of matriptase as treatment against influenza. International Proteolysis Society. Cape Town, South Africa.
  • Marsault, E. (2013). Nouveaux analogues de l’apéline: influence de la structure sur les interactions avec le récepteur et la signalisation biaisée. Journées Sherbrooke-Montpellier. Montpellier, France.
  • Boyapelly K; Le Roux A; Yan LH; Lamontagne AM; Lalonde-Séguin D; Fortier LC; Lafontaine D; Marsault E. (2013). Novel pyrimidine analogs targeting the guanine riboswitch of Clostridium difficile. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Bonin MA; Désilets A; Guérin B; Leduc R; Lepage M; Marsault E. (2013). Optimization of a near-IR probe for the detection of hepsin. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Marsault, E; Lafontaine, D; Malouin, F; Fortier, LC; Lafontaine, D. (2013). Riboswitches: an emerging paradigm in the fight against S. aureus and C. difficile. first RQRM-Neomed Scientific day. Montreal, Canada.
  • Lamontagne AM; Lalonde-Séguin D; Le Roux A; Yan LH; Boyapelly K; Mulhbacher J; Brouillette E; Allard M; Malouin F; Marsault E; Fortier LC; Lafontaine D. (2013). Riboswitches as targets for novel classes of antibiotics. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Chagnon F; Marsault E; Frost E; Guay I; Boulanger S; Mitchell G; Bouarab K; Hmamouchi R; Jacques PE; Rodrigue S; Malouin F. (2013). Steroidal alkaloids as aminoglycoside-enhancing drugs. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Boulanger S; Chagnon F; Mitchell G; Frost E; Bouarab K; Hmamouchi R; Marsault E; Malouin F. (2013). Steroidal alkaloids as aminoglycoside-enhancing drugs. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Murza A; Besserer-Offroy E; Lafrance M; Roux M; Beaudet N; Longpré JM; Leduc R; Marsault E; Sarret P. (2013). Structure-activity or the apelin peptide and role in pain. Annual meeting - Society for Neurosciences. San Diego, United States.
  • Mona C; Lefrançois M; Lefebvre MR; Leduc R; Heveker N; Marsault E; Escher E. (2013). Synthesis and SAR of synthetic agonists of the CXCR4 receptor. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Le Roux A; Yan LH; Boyapelly K; Lamontagne AM; Lalonde-Séguin AM; Fortier LC; Lafontaine D; Marsault E. (2013). Synthesis and structure-activity relationships of new giuanine derivatives against the guanine riboswitch of Clostridium difficile. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Le Roux A; Yan LH; Boyapelly K; Lamontagne AM; Archambault MA; Lalonde-Séguin D; Fortier LC; Lafontaine D; Marsault E. (2013). Synthesis of new guanine derivatives and biological activity against Clostridium difficile by targeting guanine riboswitch. 2e journée scientifique du RQRM. Montreal, Canada.
  • 6. Désilets A; Colombo E; Béliveau F; Dion S; Duchêne D; Najmanovich R; Marsault E; Leduc R. (2013). TMPRSS6 comme cible thérapeutique potentielle dans les maladies associées au métabolisme du fer. 2e journée scientifique du RQRM. Montreal, Canada.
  • Desroches A; Boucher D; Blais V; Marsault E; Denault JB. (2013). The best part of caspase 7 Story is still to come. ; International Proteolysis Society. Cape Town, South Africa.
  • Colombo E; Désilets A; Beaulieu A; Marois I; Duchêne D; Najmanovich R; Leduc R; Richter M; Marsault E. (2013). Understanding the SAR of new inhibitors of matriptase. Canadian Society for Chemistry National Meeting. Québec, Canada.
  • Marsault, E. (2013). Une nouvelle classe d’antiviraux contre l’influenza. Congrès de l’axe inflammation douleur. Orford, Canada.
  • Tremblay H; Hara T; Hirasawa A; Tsujimoto; Marsault E. (2012). Agonistes de FFARs: synthèse et optimisation. Journée Phare. Orford, Canada.
  • Lafrance M; Murza A; Besserer-Offroy E; Bossé S; Beaudet N; Leduc R; Stroh T; Marsault E; Sarret P*. (2012). Analgesic aeffect of apelin and peptidomimetic analogs on pain modulation. International Association for the Study of Pain. Milano, Italy.
  • Guay I; Chagnon F; Mitchell G; Bouarab K; Marsault E; Malouin F*. (2012). Antibacterial spectrum amd structure-activity relationship of tomatidine analogs. ICAAC. San Francisco, United States.
  • Besserer-Offroy, E; Longpré, JM; Devost, D; Breton, B; Le Gouill, C; Bouvier M; Marsault E; Sarret P; Leduc R. (2012). BRET-based assay development for new GPCR ligand discovery. Journée Phare. Orford, Canada.
  • Murza A; Parent A; Besserer-Offroy E; Beaudet N; Sarret P; Marsault E. (2012). Elucidation of the structure-activity of apelin: influence of unnatural amino acids on binding, signalind and plasma stability. European Peptide Symposium. Athens, Greece, Greece.
  • Murza A; Parent A; Besserer-Offroy E; Beaudet N; Sarret P; Marsault E. (2012). Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signalling and plasma stability. Journée Phare. Orford, Canada.
  • Marsault, E. (2012). Extending chemical space for undruggable targets with the help of macrocycles. Bayer workshop on protein-protein interactions. Berlin, Germany.
  • Desroches A; Boucher D; Blais V; Marsault E; Denault JB. (2012). Faire le Parpty avec la caspase-7. Journée Phare. Orford, Canada.
  • Duchêne D; Gaudreault F; Colombo E; Désilets A; Leduc R; Marsault E; Najmanovich R. (2012). In silico development of a new series of matriptase inhibitors. Journée Phare. Orford, Canada.
  • Duchêne D; Gaudreault F; Colombo E; Désilets A; Leduc R; Marsault E; Najmanovich R*. (2012). In silico development of a new series of matriptase inhibitors. Proteo meeting. Sherbrooke, Canada.
  • Gravel E; Beaulieu A; Cloutier A; Colombo E; Marois I; Désilets A; Verreault C; Leduc R; Marsault E; Richter MV. (2012). Involvement of matriptase in influenza virus activation and multicycle replication in the human airway epithelium. Journée Phare. Orford, Canada.
  • Marsault, E. (2012). Medicinal chemistry in drug discovery. 4th Summer School on Medicines. Montréal, Canada.
  • Marsault E*; Colombo E; Duchêne D; Désilets A; Beaulieu A; Najmanovich R; Richter M; Leduc. (2012). New matriptase inhibitors as potential anti-influenza agents. CSC National Meeting. Calgary, Canada.
  • Chagnon F; Guay I; Mitchell G; Bouarab K; Malouin F; Marsault E*. (2012). Optimization of a novel steroid alkaloid antibiotic efficient against persistent forms of Staphylococcus aureus. CSC National Meeting. Calgary, Canada.
  • Mona C; Lefrançois M; Osborne A; Lefebvre MR; Heveker N; Marsault E; Escher E. (2012). Synthesis of CXCR4 specific peptidomimetic agonists: influence of flexible and rigid unnatural amino acids on binding and signallin. European Peptide Symposium. Athens, Greece, Greece.
  • Mona C; Lefrançois M; Osborne A; Lefebvre MR; Heveker N; Marsault E; Escher E. (2012). Synthesis of CXCR4 specific peptidomimetic agonists: influence of flexible and rigid unnatural amino acids on binding and signalling. Journée Phare. Orford, Canada.
  • Boulanger S; Mitchell G; Frost E; Marsault E; Bouarab K; Malouin F*. (2012). Tomatidine is bactericidal against Staphylococcus aureus in co-culture with Pseudomonas aeruginosa strains producing HQNO. ICAAC San Francisco, September 2012. San Francisco, United States.
  • Marsault, E. (2011). De l’industrie à l’académique. 1ere journée scientifique du RQRM. Montreal, Canada.
  • Colombo E; Chagnon F; Désilets A; Duchêne D; Najmanovich R; Leduc R; Marsault E. (2011). Design and synthesis of peptidomimetic inhibitors of matriptase. National Meeting of the Canadian Society for Chemisty. Montreal, Canada.
  • Lafrance M; Murza A; Bossé S; Beaudet N; Stroh T; Marsault E; Sarret P*. (2011). Involvement of the apelinergic system in pain modulation. 41TH Annual Meeting-Society for Neurosciences. (11/2011), Washington DC (USA). Washington, United States.
  • Marsault, E. (2011). Macrocyclic peptidomimetics: from concept to clinics. Québec-Israel joint symposium in drug discovery. Jerusalem, Israel.
  • Colombo E; Désilets A; Duchêne D; Najmanovich R; Leduc R; Marsault E*. (2011). Nouveaux inhibiteurs de la matriptase: structure, synthèse, activité biologique. Club des Recherches Cliniques du Québec. Tremblant, Canada.
  • Beignet J; Pinault JF; Phoenix S; Beaubien S; Mathieu A; Leclerc P; Berthiaume N; Thomas H; Marsault E*. (2011). Nouvelle synthèse de la L-?-méthyl cyclopropylglycine et influence sur l’activité biologique des modulateurs du récepteur de la ghréline. Colloque de chimie médicinale, 79e congrès de l’ACFAS. Sherbrooke, Canada.
  • Murza A; Tremblay H; Karadereye F; Parent A; Beaudet N; Sarret P; Marsault E*. (2011). Relation structure/activité et études de stabilité plasmatique d’analogues peptidiques de l’apéline. Colloque de chimie médicinale, 79e congrès de l’ACFAS. Sherbrooke, Canada.
  • Tremblay H; Trottier A; Chagnon F; Beauregard A; Leclerc P; Langlois MF; Marsault E*. (2011). Synthesis and optimization of bifunctional agonists of the GPR40 and PPAR? receptors. National Meeting of the Canadian Society for Chemisty. Montreal, Canada.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.